The Symptom Nobody Names

There is a cluster of symptoms that affects the majority of women eventually, that gets steadily worse without treatment, that responds extremely well to a cheap and safe treatment — and that most women never mention to anyone.

It has a formal name now: genitourinary syndrome of menopause. The name was agreed in 2014 by two professional societies, deliberately replacing "vaginal atrophy", partly because the old term was medically incomplete and partly because it was a horrible thing to say to a woman.

What it covers

Falling estrogen affects tissue in the vulva, vagina, urethra and bladder, all of which are estrogen-responsive. The result can include:

Vaginal dryness. Burning or irritation. Pain during sex, ranging from mild to severe enough that sex stops entirely. Reduced lubrication and reduced elasticity. Light bleeding after sex. Urinary urgency — the sudden need to go, immediately. More frequent urinary tract infections. Discomfort on urinating with no infection present.

Estimates of prevalence vary with how the question is asked, but the range typically reported is roughly half to two thirds of postmenopausal women. The proportion who raise it with a clinician is far smaller, and the proportion who receive treatment smaller again.

Why this one is different

Hot flushes eventually resolve for most women. Genitourinary symptoms don't. They're progressive, because the underlying tissue change continues rather than passing through a transitional phase.

Which means the standard strategy — wait it out, manage around it — reliably fails here. Women who wait typically find it worse in five years, and by then a manageable dryness has often become pain that has reorganised an entire relationship.

The treatment, and why the fear around it is misplaced

Local vaginal estrogen is the primary treatment: a cream, pessary, tablet or ring used vaginally. It works, with strong evidence.

The near-universal question is whether it's safe, and the concern usually traces back to what women have absorbed about systemic hormone therapy. The distinction is important. Local vaginal estrogen is low-dose and acts largely where it's applied, with minimal absorption into the bloodstream. It's a fundamentally different exposure from systemic HRT.

Two things underline this. Professional guidance supports its use without routine progestogen for endometrial protection in most women, because systemic levels stay so low. And in November 2025 the FDA, having reviewed the evidence, moved to remove the boxed warnings from estrogen-containing menopause products — vaginal estrogens included.

For most women with breast cancer history the picture requires an individual conversation with their oncology team, and guidance from menopause and sexual health societies notes that low-dose vaginal estrogen may be appropriate for selected women when non-hormonal options haven't worked. That is a conversation to have with your team, not a decision to make from an article.

Non-hormonal options also help and are available without prescription. Vaginal moisturisers, used regularly rather than only before sex, improve baseline tissue comfort. Lubricants address friction during sex. They're complementary to estrogen, not substitutes for it — moisturisers hydrate tissue but don't reverse the underlying change.

There's also prasterone (vaginal DHEA) and, in some countries, ospemifene, an oral option. NICE's 2024 update revised its recommendations on managing genitourinary symptoms, and it's reasonable to ask what applies to you.

The conversation

The reason this is under-treated isn't clinical. It's that nobody says it out loud.

There's no version of this that isn't a little awkward, so the practical approach is to be direct and get through it. "I'm having vaginal dryness and pain with sex, and I'd like to discuss vaginal estrogen." One sentence. It signals what you want, uses the correct terminology, and skips the part where you're both circling.

If you're not sexually active, the symptoms still matter — urinary urgency, recurrent infections and daily discomfort don't depend on sex, and treatment helps regardless.

If you don't get taken seriously, that's grounds to ask for a second opinion or a referral to someone with menopause expertise. This is one of the best-evidenced, lowest-risk, highest-benefit treatments in the entire field, and being sent away with a tube of lubricant is not adequate care.

The bit that matters

Painful sex frequently gets attributed to the relationship, or to desire, or to something the woman has decided is wrong with her. Often the cause is tissue, and tissue is treatable.

That's worth knowing before years pass.

Sources

- Portman DJ, Gass MLS. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society. Menopause. 2014;21(10):1063–1068. - The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976–992. - National Institute for Health and Care Excellence. Menopause: identification and management (NG23), genitourinary recommendations. Updated 2024. - US Food and Drug Administration. FDA requests labeling changes for menopausal hormone therapies. 10 November 2025. - Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. Menopause. 2018;25(6):596–608.